The clinical trials of Bharat Biotech's intranasal booster vaccine-BBV154 will be started on March 18 by the All India Institute of Medical Sciences in New Delhi. In January 2021, this Hyderabad-based pharmaceutical company received permission from the Drugs Controller General of India to conduct the clinical trials of the vaccine.
The Chairman of the company, Krishna Ella said that this vaccine is the best choice for babies and other people but cannot be administered to cancer patients and pregnant women.
To be carried out in different locations, people above the age of 18 will be vaccinated with this vaccine in the phase 3 trial. The registration can be done either through Whatsapp or through email.
Prior to Delhi, Pune has gone through the trial test of this vaccine. A target of vaccinating one billion doses in a year was made by Bharat Biotech in December lastPrior to Delhi, Pune has gone through the trial test of this vaccine. A target of vaccinating one billion doses in a year was made by Bharat Biotech in December last.
The benefits of an intranasal vaccine is that it stimulates a broad immune response-neutralizing IgG, mucosal IgA, and T Cell response.
The immune response at the site of infection (in the nasal mucosa)-is essential for blocking both the infection and the transmission of Covid-19. The nasal route has excellent potential for vaccination due to the organized immune system of the nasal mucosa. The nasal vaccines are easy to be administered and do not require any trained health care worker. This vaccine is able to meet global demands.